Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM103 Alone and With Pembrolizumab in Advanced Solid Tumors
NCT06265025Phase 2Recruiting
- Sponsor
- GeneMedicine Co., Ltd.
- Start
- Feb 2024
- Primary completion
- May 2025
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label trial of oAd-IL12-shVEGF in head and neck cancer (HNC), Malignant Melanoma (MM), colorectal cancer (CRC) and 4 more (3 arms), sponsored by GeneMedicine Co., Ltd. Primary endpoints: Percentage of patients with Dose Limiting Toxicities (DLTs) by cohorts at 28 days, Percentage of patients with Dose Limiting Toxicities (DLTs) at 21 days and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
oAd-IL12-shVEGF
03
Conditions
head and neck cancer (HNC)Malignant Melanoma (MM)colorectal cancer (CRC)renal cell carcinoma (RCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06265025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06265025.